Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Summarize this article with:
SA Transcripts157.27K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy December 9, 2025 3:00 PM EST Company Participants Louis Tamayo - CFO & Principal Accounting OfficerEric Adler - Chief Medical Officer & Head of ResearchVictoria Parikh Conference Call Participants Geulah Livshits - Chardan Capital Markets, LLC, Research DivisionMatthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research DivisionBrian Skorney - Robert W. Baird & Co. Incorporated, Research DivisionMariam Waggeh - JPMorgan Chase & Co, Research DivisionLeland Gershell - Oppenheimer & Co. Inc., Research DivisionHongye Wei - Guggenheim Securities, LLC, Research DivisionKristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Operator Good afternoon, and welcome to the fireside chat titled: A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy, hosted by Lexeo Therapeutics. As a reminder, this call is being recorded today, Tuesday, December 9. I would now like to turn the call over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead. Louis TamayoCFO & Principal Accounting Officer Thank you. Welcome to this fireside chat session. Joining us today on the call from DC where they are both participating in the Cardiovascular Clinical Trialists Forum are Dr. Eric Adler of Lexeo Therapeutics; and Dr. Victoria Parikh, Clinician, Scientist and Director of the Stanford Center for Inherited Cardiovascular Disease at Stanford School of Medicine. Before we begin, I would like to remind you that this call may contain forward-looking statements regarding Lexeo's future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our filings with the SEC. Additionally, both Dr. Adler and Recommended For You